OncoMatch/Clinical Trials/NCT06889766
NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
Is NCT06889766 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including NY-ESO-1 TCR redirected autologous T cell product and Non-myeloablative lymphodepleting chemotherapy for advanced melanoma.
Treatment: NY-ESO-1 TCR redirected autologous T cell product · Non-myeloablative lymphodepleting chemotherapy — A single center, Phase I clinical trial to demonstrate safety and efficacy of LauT-1, autologous "New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor (NY-ESO-1 TCR)-directed T cells in combination with non-myeloablative (NMA) lymphodepleting chemotherapy and low dose irradiation (LDI) in patients with NY-ESO-1 positive sarcoma and melanoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Sarcoma
Biomarker criteria
Required: CTAG1B immunohistochemically documented expression (≥ 1+ in ≥50% of tumor tissue) (≥ 1+ in ≥50% of tumor tissue)
Immunohistochemically documented NY-ESO-1 expression, defined as ≥ 1+ expression on either archival or fresh tumor tissue by immunohistochemistry, in ≥50% of the sampled tumor tissue.
Required: BRAF wild-type
Without proto-oncogene B-Raf (BRAF) mutation
Allowed: BRAF mutation
With BRAF mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy — sarcoma
Patients with sarcoma, who have received at least one line of standard therapy (if available) and failed to respond, progressed or were intolerant to that therapy
Must have received: standard therapy — metastatic melanoma, BRAF wild-type
Without proto-oncogene B-Raf (BRAF) mutation who have received at least one line of standard therapy and failed to respond, progressed or were intolerant to that therapy
Must have received: standard therapy — metastatic melanoma, BRAF mutation
With BRAF mutation who have received at least two lines of standard therapy and failed to respond, progressed or were intolerant to that therapy
Cannot have received: allogeneic stem cell transplantation
Patients with prior allogeneic stem cell transplantation or organ transplantation
Cannot have received: organ transplantation
Patients with prior allogeneic stem cell transplantation or organ transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify